Case report: Treatment with ensartinib shows good response to SQSTM1-ALK fusion in lung adenocarcinoma

• Ngā kaituhi matua: Pandeng Wang (Author), Zhuo Jiang (Author), Jianji Guo (Author), Tao Liu (Author), Zhen Liu (Author), Dongdong Wang (Author), Honglin Li (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2024-11-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Lung cancer is a prevalent malignancy, with the rearrangement of the anaplastic lymphoma kinase (ALK) gene being responsible for a minority of cases of non-small cell lung cancer (NSCLC). NSCLC patients harboring ALK fusion proteins demonstrate sensitivity to ALK tyrosine kinase inhibitors (TKIs). I...